论文部分内容阅读
目的:探讨厄洛替尼在营养不良状态大鼠体内药动学特征.方法:建立营养不良状态大鼠模型.模型组和正常对照组分别尾静脉注射厄洛替尼溶液(6.25 mg·kg-1),或口服给予厄洛替尼溶液和厄洛替尼混悬液(13.5 mg·kg-1),于给药后不同时间点采集血样,采用HPLC法测定血浆中厄洛替尼的含量,计算药动学参数.结果:统计相比,营养不良大鼠口服溶液剂的Tmax较正常状态大鼠明显延迟(P0.05).而口服混悬液组,营养不良大鼠的Tmax相对正常状态大鼠明显降低,AUC0~t、AUC0~∞均明显增加(P<0.05).同时营养不良大鼠口服溶液剂和混悬剂组的清除率(CL)相对正常状态大鼠均降低约10%(P<0.05).结论:营养不良状态对厄洛替尼体内的药动学行为有显著影响,提示临床上营养不良患者使用厄洛替尼时需要对治疗方案进行调整.“,”Objective:To investigate the pharmacokinetics of erlotinib in SD rats with undernourished status. Methods:The ani-mal model of undernourished status was established. The rats were randomly divided into the normal control group and the undernour-ished model group. The different groups were administered with erlotinib(6.25 mg·kg-1) via tail vein,and administered with erlo-tinib (13.5 mg·kg-1) oral solution or oral suspension. The plasma concentration of erlotinib was determined by HPLC. The pharma-cokinetic parameters were calculated. Results:Compared with that of the normal control group, Tmaxin the rats with undernourished status was significantly delayed(P0.05). As for the oral sus-pension,Tmaxwas shorter,and AUC0~tand AUC0~∞were higher in the rats with undernourished status than those in the rats with nor-mal status(P<0.05). CL in the rats with undernourished status treated with oral solution or oral suspension was 10% lower than that in the rats with normal status(P<0.05). Conclusion:Undernourished status has a significant impact on the pharmacokinetics of er-lotinib in vivo. It is suggested that the treatment regimen of erlotinib should be adjusted for the patients with undernourished status.